Solara Active Pharma Sciences Reports Q1 Results, Reaches Profit Amid Accumulated Losses

Solara Active Pharma Sciences Reports Q1 Results, Reaches Profit Amid Accumulated Losses​

Solara Active Pharma Sciences Limited has released its unaudited financial results (standalone and consolidated) for the quarter ended June 30, 2026. The Board of Directors approved these results following a meeting held on July 23, 2026.

The company’s operations focus on the Active Pharmaceutical Ingredient (API) segment. These financial outcomes include both current quarterly performance and detailed comparisons against preceding periods.

Consolidated Financial Performance Highlights​

The consolidated unaudited financial results for Solara Active Pharma Sciences Limited and its subsidiaries reflect a profitable quarter, although management notes significant accumulated losses within the group.

Key data points from the Statement of Unaudited Consolidated Financial Results are presented below (figures in Crores):


The results also indicate that while the Group reported a profit of Rs. 16.31 crores for the quarter, as of June 30, 2026, it has accumulated losses amounting to Rs. 286.21 crores.

Standalone Financial Performance Highlights​

Similarly, the standalone unaudited financial results show operational success for the company in the third quarter, contrasting with long-term group performance metrics.

Standalone figures (figures in Crores) are summarized as follows:


The standalone results show the company achieving a profit of Rs. 16.99 crores for the quarter ended June 30, 2026. However, corresponding to the consolidated view, the company has accumulated losses of Rs. 285.73 crores as of June 30, 2026.

Corporate Updates and Financial Standing​

The Board of Directors approved the preparation of these results on a going concern basis, confident in renewing working capital facilities and increasing revenues through product margin enhancement to meet future obligations.

The consolidated financial results incorporate interim information from two subsidiaries whose auditors had not reviewed them, including data points such as total revenue of Rs. Nil and total net loss after tax of Rs. 0.01 Crores for the quarter ended June 30, 2026.

In operational matters, the company previously granted in-principle approval to explore a demerger of its CRAMS and Polymers business into an independent listed entity, leading to the incorporation of Synthix Global Pharma Solutions Limited on April 29, 2025. The group's operations currently consist of three entities: Solara Active Pharma Sciences Limited (the Parent), Shasun USA Inc. (wholly owned subsidiary), and Chemsynth Laboratories Private Limited (subsidiary), along with Synthix Global Pharma Solutions Limited (wholly owned subsidiary).

The company had previously offered up to 1,19,98,755 Equity shares on a rights basis in May 2024, having since raised Rs. 442.73 crores out of the total size of Rs. 449.95 crores.

SOLARA Stock Price Movement​

Shares of Solara Active Pharma Sciences Limited are advancing to ₹538.55 as of 1:31 PM today, posting a 0.45% gain in the ongoing market session. The stock exhibits strong intraday activity, trading over 250,451 shares and currently holding up well above its daily low of ₹530.1.